Journal article
Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer
A Bonaventura, RL O'Connell, C Mapagu, PJ Beale, OM McNally, LR Mileshkin, PT Grant, AM Hadley, JCH Goh, KM Sjoquist, J Martyn, A DeFazio, J Scurry, ML Friedlander
International Journal of Gynecological Cancer | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
Background: There is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. The Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptorYpositive recurrent gynecological cancers. We report the results of treatment in patients with platinum-resistant or -refractory recurrent epithelial ovarian cancer. Methods: Postmenopausal women who had estrogen and/or progesterone receptorYpositive platinum-resistant or platinum-refractory recurrent ovarian cancer and disease measurable by Response Evaluation Criteria In Solid Tumors (RECIST) ..
View full abstractGrants
Awarded by Cancer Australia
Awarded by Priority-driven Collaborative Cancer Research
Funding Acknowledgements
The study was funded by grants from Cancer Australia (grant 632740) and Priority-driven Collaborative Cancer Research (scheme 1063014). Anastrozole was provided by AstraZeneca.